Waldenstrom's Macroglobulinemia News 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.New Waldenstrom's drug shows sustained benefit at two years
Ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years, research concludes. The disease stems from an abnormality in B lymphocytes in the bone marrow causing them to overproduce IgM, an immunoglobulin protein that thickens the blood; patients may experience bleeding, dizziness, headaches, weight loss, bruising and nerve damage. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - April 9, 2015 Category: Science Source Type: news
New Waldenstrom's drug shows sustained benefit at two years
(Dana-Farber Cancer Institute) Dana-Farber researchers report in the New England Journal of Medicine that ibrutinib, a newly approved drug for Waldenstrom's Macroglobulinemia, continues to control the rare blood cancer, with 95 percent of patients surviving for two years. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 9, 2015 Category: Global & Universal Source Type: news
'New Era' in the Treatment of Rare Lymphoma'New Era' in the Treatment of Rare Lymphoma
Ibrutinib is the first drug approved for the treatment of Waldenström's macroglobulinemia, and new data strengthen its profile. Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - April 8, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
Genetics Home Reference: Waldenström macroglobulinemia
http://ghr.nlm.nih.gov/condition/waldenstrom-macroglobulinemia (Source: NLM General Announcements)
Source: NLM General Announcements - April 7, 2015 Category: Databases & Libraries Source Type: news
FDA Expands Imbruvica Use for Non-Hodgkin Lymphoma
Imbruvica (ibrutinib) can now be prescribed for patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system (Source: PharmaManufacturing.com)
Source: PharmaManufacturing.com - February 4, 2015 Category: Pharmaceuticals Source Type: news
Ibrutinib Approved in US for Rare LymphomaIbrutinib Approved in US for Rare Lymphoma
This is the first drug ever to be approved for the treatment of Waldenstrom's macroglobulinemia since the disease was described 70 years ago. FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 30, 2015 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news
Janssen and Pharmacyclics receive FDA approval for Imbruvica to treat WM
Janssen Biotech and Pharmacyclics have received approval from the US Food and Drug Administration (FDA) for Imbruvica (ibrutinib) capsules as the first therapy indicated specifically for patients with Waldenström's macroglobulinemia (WM), a rare, ind… (Source: Pharmaceutical Technology)
Source: Pharmaceutical Technology - January 30, 2015 Category: Pharmaceuticals Source Type: news
FDA expands use of Imbruvica to treat rare form of blood cancer
(Reuters) - The U.S. Food and Drug Administration said it cleared an expanded use of Imbruvica to treat Waldenström's macroglobulinemia (WM), a rare form of blood cancer for which no specific pharmaceutical therapy exists. (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2015 Category: Consumer Health News Tags: healthNews Source Type: news
FDA expands approved use of Imbruvica for rare form of non-Hodgkin lymphoma
The U.S. Food and Drug Administration today expanded the approved use of Imbruvica (ibrutinib) for previously treated patients with Waldenström’s macroglobulinemia (WM), a rare form of cancer that begins in the body’s immune system. The drug received a breakthrough therapy designation for this use. (Source: Food and Drug Administration)
Source: Food and Drug Administration - January 29, 2015 Category: American Health Source Type: news
Cloning Variable Region Genes of Clonal Lymphoma Immunoglobulin for Generating Patient-Specific Idiotype DNA vaccines
Available therapies for lymphoplasmacytic lymphoma (LPL) provide no survival advantage if started before signs or symptoms of end-organ damage develop; hence, current recommendations are to follow a program of observation while patients are in the asymptomatic phase of disease. We hypothesize that using idiotypic determinants of a B-cell lymphoma’s surface immunoglobulin as a tumor-specific marker, we can develop patient-specific chemokine-idiotype fusion DNA vacciness that induce an immune response against LPL. By activating the host immune system against the tumor antigen, we postulate that disease control of asymp...
Source: Springer protocols feed by Cancer Research - April 7, 2014 Category: Cancer & Oncology Source Type: news
Discovery of CXCR4 mutations in Waldenstrom's Macroglobulinemia helps identify which patients are more likely to benefit from ibrutinib
In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions reported at the 2013 annual meeting of the American Society of Hematology (ASH). The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation.Waldenstrom's is a form of non-Hodgkin lymphoma diagnosed in 2,000 to 3,000 people in the United States each year. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - December 11, 2013 Category: Consumer Health News Tags: Lymphoma / Leukemia / Myeloma Source Type: news
Gene 'driver' of Waldenstrom's Macroglobulinemia in up to one-third of patients identified
(Dana-Farber Cancer Institute) In nearly one-third of patients with Waldenstrom's Macroglobulinemia, a specific genetic mutation switches on the disease, and a new drug that blocks the defective gene can arrest the disease in animal models, researchers at Dana-Farber Cancer Institute and allied institutions will report at the 2013 annual meeting of the American Society of Hematology. The finding may open the way to clinical trials of the drug in Waldenstrom's patients whose tumor cells carry the mutation. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 9, 2013 Category: Global & Universal Source Type: news
Pharmacyclics reports results of Ibrutinib Phase II study for Waldenstrom's Macroglobulinemia
Clinical-stage biopharmaceutical company Pharmacyclics has announced results from Phase II study of oral Bruton's tyrosine kinase (BTK) inhibitor, Ibrutinib, conducted in patients with Waldenstrom's Macroglobulinemia (WM). (Source: Drug Development Technology)
Source: Drug Development Technology - June 20, 2013 Category: Pharmaceuticals Source Type: news
FDA grants 'Breakthrough Therapy Designation' to ibrutinib for treatment of relapsed or refractory mantle cell lymphoma and Waldenstrom's macroglobulinemia
Source: BioSpace , PharmaTimes
Area: News
The FDA has granted 'Breakthrough Therapy Designation' to ibrutinib (as monotherapy) for the treatment of patients with relapsed or refractory mantle cell lymphoma (MCL) and for the treatment of patients with Waldenstrom's macroglobulinemia (WM).
Ibrutinib is an investigational oral agent designed to specifically target and selectively inhibit an enzyme called Bruton's tyrosine kinase (BTK), a key mediator of at least three critical B-cell pro-survival mechanisms occurring in parallel regulating apoptosis, adhesion, and cell migration and homing.
The Breakt...
Source: NeLM - News - February 14, 2013 Category: Drugs & Pharmacology Source Type: news
